Virpax Pharma Gets Government Cooperation Deal Extension

Dow Jones11-22

By Dean Seal

Virpax Pharmaceuticals said the federal government has extended a collaboration on the development of Virpax's pain treatment.

The company said Thursday that the extended cooperative research and development agreement with the National Center for Advancing Translational Sciences is a boon for NES100, its product candidate for managing acute and chronic non-cancer pain.

The National Center for Advancing Translational Sciences is an institute of the National Institutes of Health, part of the U.S. Department of Health and Human Services.

The company's stock more than doubled to $1.21 in after hours trading after the extension was announced.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

November 21, 2024 16:41 ET (21:41 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485342686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485342686","market":"other","top_or_hot":-1,"title":"Virpax Pharma Gets Government Cooperation Deal Extension","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  Virpax Pharmaceuticals said the federal government has extended a collaboration on the development of Virpax's pain treatment. \n</p>\n<p>\n  The company said Thursday that the extended cooperative research and development agreement with the National Center for Advancing Translational Sciences is a boon for NES100, its product candidate for managing acute and chronic non-cancer pain. \n</p>\n<p>\n  The National Center for Advancing Translational Sciences is an institute of the National Institutes of Health, part of the U.S. Department of Health and Human Services. \n</p>\n<p>\n  The company's stock more than doubled to $1.21 in after hours trading after the extension was announced. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 21, 2024 16:41 ET (21:41 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Virpax Pharma Gets Government Cooperation Deal Extension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVirpax Pharma Gets Government Cooperation Deal Extension\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 05:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Dean Seal \n\n\n  Virpax Pharmaceuticals said the federal government has extended a collaboration on the development of Virpax's pain treatment. \n\n\n  The company said Thursday that the extended ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRPX","symbol_name":"Virpax Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485342686","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485342686","pubTimestamp":1732225260,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Virpax Pharmaceuticals said the federal government has extended a collaboration on the development of Virpax's pain treatment.The company said Thursday that the extended cooperative research and development agreement with the National Center for Advancing Translational Sciences is a boon for NES100, its product candidate for managing acute and chronic non-cancer pain.The National Center for Advancing Translational Sciences is an institute of the National Institutes of Health, part of the U.S. Department of Health and Human Services.The company's stock more than doubled to $1.21 in after hours trading after the extension was announced.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRPX":"Virpax Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Virpax Pharma获得政府合作协议延期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRPX":0.9},"content_text":"By Dean Seal \n\n\n  Virpax Pharmaceuticals said the federal government has extended a collaboration on the development of Virpax's pain treatment. \n\n\n  The company said Thursday that the extended cooperative research and development agreement with the National Center for Advancing Translational Sciences is a boon for NES100, its product candidate for managing acute and chronic non-cancer pain. \n\n\n  The National Center for Advancing Translational Sciences is an institute of the National Institutes of Health, part of the U.S. Department of Health and Human Services. \n\n\n  The company's stock more than doubled to $1.21 in after hours trading after the extension was announced. \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2024 16:41 ET (21:41 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485342686"}